Resolvyx Pharmaceuticals is dedicated to the discovery and development of therapeutics for inflammatory diseases. Based on pioneering work from the Laboratory of Professor Charles Serhan of Brigham and Women's Hospital in Boston, this early-stage company is defining a new medical paradigm of controlling inflammation by activating endogenous resolution pathways. The promise is to provide highly effective drugs, with outstanding risk-benefit profiles, for a wide range of acute and chronic diseases representing markets well over $10B. Flagship co-led the Series A financing in 2005, and Partner Doug Levinson is on the Board.

www.resolvyx.com